takeaway ms expert call
call dr gutstein proprietari ms survey find
support view ms franchis declin near term dr
gutstein state prefer gilenya possibl gener vs tecfidera
posit tysabri survey indic broad prefer
ocrevu iv space still think consensu fulli appreci
headwind ms franchis combin neg view
sma franchis current capit alloc strategi rate share
under-perform tp
tecfidera could see greater share captur novarti gilenya dr
gutstein view tecfidera less favor novarti gilenya saw
gilenya daili single-tablet regimen differenti also believ
gilenya first dose monitor less concern follow
observ period patient tend prefer profil asset
oral gener could compress tecfidera physician posit
potenti gener entri next year open start newli
diagnos patient gener view efficaci among oral rel
similar suggest gener use could insur mandat like
step-wis initi use gener ahead brand drug
avonex plegridi inject expect declin physician
believ market inject limit highlight low patient
satisfact vs oral inferior efficaci compar iv option
vumer could take share tecfidera greater oral market
dr gutstein view next-gener ms asset vumer larg
undifferenti compar tecfidera acknowledg vumer lower
gi side effect benefici two-tablet regimen titrat would
drive prefer gilenya
tysabri like see modest eros ocrevu therapi less
impact physician posit tysabri roch ocrevu
note captur signific share view requir
genet test novarti mayzent potenti limit
call replay id pleas ask us call transcript
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater expect rate new therapi take greater
expect share near-term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
compani mention price
